according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

### **SECTION 1. IDENTIFICATION**

Product name : Halofuginone Formulation Other means of identification : HALOCUR (A009802)

HALOCUR ORAL SOLUTION FOR TREATMENT OF

CALVES (57163)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

### **SECTION 2. HAZARDS IDENTIFICATION**

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Skin irritation : Category 2

Eye irritation : Category 2A

Other hazards

None known.

GHS label elements

Hazard pictograms :

<u>(!</u>)

Signal Word : Warning

Hazard Statements : H315 Causes skin irritation.

H319 Causes serious eye irritation.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P280 Wear protective gloves, eye protection and face protec-

tion.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

according to the OSHA Hazard Communication Standard



# Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 04/14/2025 845725-00023 Date of first issue: 08/26/2016 8.0

> P332 + P313 If skin irritation occurs: Get medical attention. P337 + P313 If eye irritation persists: Get medical attention. P362 + P364 Take off contaminated clothing and wash it before

reuse.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
	50-21-5*	>= 0.5 - <= 1.5	TSC
Halofuginone	82186-71-8*	<= 0.1	TSC

Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of contact, immediately flush eyes with plenty of water In case of eye contact

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

Causes skin irritation.

Causes serious eye irritation.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not get on skin or clothing.

Avoid inhalation of vapor or mist.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Halofuginone	82186-71-8	TWA	5 μg/m3 (OEB 4)	Internal	
	Further information: DSEN, Skin				
		Wipe limit	50 μg/100 cm <sup>2</sup>	Internal	

## **Engineering measures**

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version 8.0

Revision Date: 04/14/2025

SDS Number: 845725-00023

Date of last issue: 12/03/2024 Date of first issue: 08/26/2016

potential exists for aerosolization. If this potential does not

exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection

General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

## **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : yellow

Odor : odorless

Odor Threshold : No data available

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

pH : 2.1 - 3

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

: Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

### **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

## **Components:**

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Halofuginone:

Acute oral toxicity : LD50 (Rat): 30 mg/kg

LD50 (Mouse): 5 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.053 mg/l

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 16 mg/kg

#### Skin corrosion/irritation

Causes skin irritation.

### **Components:**

#### Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Halofuginone:

Species : Rabbit Result : Skin irritation

## Serious eye damage/eye irritation

Causes serious eye irritation.

### Components:

### Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

Halofuginone:

Result : Severe irritation

### Respiratory or skin sensitization

### Skin sensitization

Not classified based on available information.

### Respiratory sensitization

Not classified based on available information.

### **Components:**

### Lactic acid:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

Halofuginone:

Routes of exposure : Dermal
Species : Guinea pig
Result : Sensitizer

## Germ cell mutagenicity

Not classified based on available information.

### **Components:**

#### Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

## Halofuginone:

Genotoxicity in vitro : Test Type: Ames test

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Test Type: Cytogenetic assay

Species: Rat

Application Route: Oral Result: negative

Test Type: DNA Repair

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

> Species: Mouse Application Route: Oral Result: negative

## Carcinogenicity

Not classified based on available information.

### **Components:**

#### Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

### Halofuginone:

Species : Mouse Application Route : Oral

NOAEL : 0.24 mg/kg body weight

Result : negative

Species : Rat
Application Route : Oral
Exposure time : 63 weeks

NOAEL : 0.36 mg/kg body weight

Result : negative

Species : Rat
Application Route : Oral
Exposure time : 26 Months

NOAEL : 0.09 - 0.18 mg/kg body weight

Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Not classified based on available information.

#### **Components:**

### Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

Application Route: Ingestion

Result: negative

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

П

Halofuginone:

Effects on fertility : Test Type: Fertility

Species: Mouse Application Route: Oral

Fertility: NOAEL: 0.126 mg/kg body weight

Result: No effects on fertility.

Test Type: Fertility Species: Dog

Application Route: Oral

Fertility: LOAEL: 0.067 mg/kg body weight

Result: Effects on fertility.

Test Type: Three-generation reproduction toxicity study

Species: Mouse Application Route: Oral

General Toxicity F1: LOAEL: 0.063 mg/kg body weight

Symptoms: Reduced body weight

Result: No effects on fertility and early embryonic

development were detected.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 0.34 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 0.67 mg/kg body weight Result: No embryo-fetal toxicity., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 0.025 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 0.076 mg/kg body weight Result: No embryo-fetal toxicity., No teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

**Components:** 

Halofuginone:

Target Organs : Blood

Assessment : Causes damage to organs through prolonged or repeated

exposure.

according to the OSHA Hazard Communication Standard



# Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

### Repeated dose toxicity

### Components:

### Lactic acid:

Species Rat

NOAEL : > 100 mg/kg Application Route : Ingestion Exposure time : 13 Weeks

Remarks Based on data from similar materials

Species Rat

Species LOAEL Application Route 886 mg/kg : Skin contact Exposure time 13 Weeks

## Halofuginone:

Species Mouse NOAEL : 0.07 mg/kg LOAEL : 0.16 mg/kg Application Route : Oral 4 Weeks Exposure time Target Organs Blood

Species Rat

NOAEL 0.13 mg/kg : LOAEL 0.88 mg/kg Application Route
Exposure time : Oral 13 Weeks Target Organs Liver

**Species** : Dog

NOAEL 0.067 mg/kg LOAEL : 0.134 mg/kg

Application Route : Oral Exposure time : 13 Weeks : Blood Target Organs

Species Dog

NOAEL 0.075 mg/kg LOAEL 0.16 mg/kg Application Route Oral Exposure time 26 Weeks Target Organs Blood

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

## **Components:**

## Halofuginone:

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

General Information : No human information is available.

Inhalation : Remarks: May cause irritation of respiratory tract.
Skin contact : Remarks: May cause skin irritation and/or dermatitis.

May cause sensitization by skin contact.

Can be absorbed through skin. Remarks: May irritate eyes.

### **SECTION 12. ECOLOGICAL INFORMATION**

## **Ecotoxicity**

Eye contact

### **Components:**

#### Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

### Halofuginone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1.8 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

LC50 (Cyprinus carpio (Carp)): 0.3 mg/l

Exposure time: 72 h

Remarks: Based on data from similar materials

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.12 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

according to the OSHA Hazard Communication Standard



# Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 04/14/2025 845725-00023 Date of first issue: 08/26/2016 8.0

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.02 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

EC50 (Chlorella pyrenoidosa): 46 mg/l Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Persistence and degradability

Components:

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

Halofuginone:

Biodegradability Result: Not readily biodegradable.

Bioaccumulative potential

Components:

Lactic acid:

Partition coefficient: n-

: log Pow: -0.62

octanol/water

Halofuginone:

Partition coefficient: n-

log Pow: 1.18

octanol/water

Mobility in soil **Components:** 

Halofuginone:

Distribution among environ- : log Koc: 3.87

mental compartments

Method: FDA 3.08

Other adverse effects

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS** 

**Disposal methods** 

Waste from residues Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Empty containers should be taken to an approved waste Contaminated packaging

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version Revision Date: SDS Number: Date of last issue: 12/03/2024 8.0 04/14/2025 845725-00023 Date of first issue: 08/26/2016

### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

### IATA-DGR

Not regulated as a dangerous good

### **IMDG-Code**

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

## **Domestic regulation**

#### **49 CFR**

Not regulated as a dangerous good

## Special precautions for user

Not applicable

## **SECTION 15. REGULATORY INFORMATION**

## **CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

## SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

## SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Skin corrosion or irritation

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### **US State Regulations**

### Pennsylvania Right To Know

Water 7732-18-5 Benzoic acid 65-85-0

## The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

Version 8.0

Revision Date: 04/14/2025


SDS Number: 845725-00023

Date of last issue: 12/03/2024 Date of first issue: 08/26/2016

#### **SECTION 16. OTHER INFORMATION**

#### **Further information**

#### NFPA 704:



Special hazard

### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice: HMIS - Hazardous Materials Identification System: IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act;

according to the OSHA Hazard Communication Standard



# **Halofuginone Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 12/03/2024

 8.0
 04/14/2025
 845725-00023
 Date of first issue: 08/26/2016

REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 04/14/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8